

Small Molecules

Rolipram

cAMP pathway activator; Inhibits type 4 cyclic nucleotide phosphodiesterases (PDE4)

Catalog # 73382
73384

5 mg
25 mg



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713


INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

Rolipram is a cell-permeable, selective inhibitor of Type 4 cyclic nucleotide phosphodiesterases (PDE4), which mediate cyclic AMP (cAMP) degradation. Rolipram preferably inhibits PDE4 isoform A ($IC_{50} = 3$ nM) over other isoforms such as B and D ($IC_{50} = 130$ and 240 nM, respectively; MacKenzie & Houslay). It inhibits interferon (IFN)- γ stimulated phosphorylation of p38 mitogen-activated protein (MAP) kinase through PDE4B and/or PDE4D isoform inhibition (MacKenzie & Houslay).

Molecular Name:	Rolipram
Alternative Names:	SB 95952, ZK 62711
CAS Number:	61413-54-5
Chemical Formula:	$C_{16}H_{21}NO_3$
Molecular Weight:	275.3 g/mol
Purity:	$\geq 98\%$
Chemical Name:	4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
Structure:	



Properties

Physical Appearance:	A crystalline solid
Storage:	Product stable at -20°C as supplied. Protect from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com .
Solubility:	· DMSO ≤ 35 mM · Absolute ethanol ≤ 15 mM For example, to prepare a 10 mM stock solution in DMSO, resuspend 5 mg in 1.82 mL of DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C . Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

REPROGRAMMING

- Induces reprogramming of adult human dermal fibroblasts (AHDFs) into induced neuronal stem cells, in combination with A83-01, CHIR99021, sodium butyrate, LPA, SP600125, and exogenous OCT4 expression (Zhu et al.).

DIFFERENTIATION

- Enhances osteoblastic differentiation of mouse mesenchymal stem cells (MSCs) induced by BMP-2 (Munisso et al.).
- Induces neural differentiation of human bone marrow-derived MSCs (Alexanian et al.).

IMMUNOLOGY

- Inhibits inflammation by suppressing leukocyte function, inhibiting C5a-stimulated leukotriene C4 (LTC4) synthesis in human eosinophils (Tenor et al.).
- Inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) synthesis in human monocytes (Souness et al.).

DISEASE MODELING

- Promotes survival of newly formed mouse hippocampal neurons in a mouse model of ischemia (Sasaki et al.).
- Reverses amphetamine-induced reductions in auditory-evoked potentials in a C57BL/6J mouse model of schizophrenia (Maxwell et al.).

References

- Alexanian AR et al. (2011) Transplanted neurally modified bone marrow-derived mesenchymal stem cells promote tissue protection and locomotor recovery in spinal cord injured rats. *Neurorehabil Neural Repair* 25(9): 873–80.
- MacKenzie SJ & Houslay MD. (2000) Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. *Biochem J* 347(Pt 2): 571–8.
- Maxwell CR et al. (2004) Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. *Neuroscience* 129(1): 101–7.
- Munisso MC et al. (2012) Cilomilast enhances osteoblast differentiation of mesenchymal stem cells and bone formation induced by bone morphogenetic protein 2. *Biochimie* 94(11): 2360–5.
- Sasaki T et al. (2007) The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia. *Stroke* 38(5): 1597–605.
- Souness JE et al. (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. *Br J Pharmacol* 118(3): 649–58.
- Tenor H et al. (1996) Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. *Br J Pharmacol* 118(7): 1727–1735.
- Zhu S et al. (2014) Small molecules enable OCT4-mediated direct reprogramming into expandable human neural stem cells. *Cell Res* 24(1): 126–9.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, please visit our website at www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

This product is hazardous. Please refer to the Safety Data Sheet (SDS).

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2016 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design and Scientists Helping Scientists are trademarks of STEMCELL Technologies Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.